CAR technology has rapidly accelerated investigations into HER2-directed gene-modified T cells in several clinical trials: NCT00902044 (for sarcoma), NCT00889954 (all HER2(+) cancers), NCT01109095 (GBM), NCT00924287 (metastatic cancer) and NCT01935843 (HER2(+) solid tumors). This evidence concerns the gene ERBB2 and sarcoma.